Coming back to: Semaglutide half-life: where the 165 to 184 hour figure comes from

Semaglutide half-life: where the 165 to 184 hour figure comes from Writing it up because I had to work it out twice and would rather nobody else did.

Putting the numbers in the first post, because a question about a compound without them turns into a question about somebody's impression of it.

semaglutide, monoisotopic mass near 4113.6 Da, 27 weeks of my own notes, and 4 lots from 4 suppliers with a purity figure on each. That is the whole basis of what follows.

What I want checked is the reasoning I have built on top of it, not the figures themselves.

Post #5 is right about the mechanism and I think understates the practical bit.

Renal outcomes moved this compound out of the metabolic-only conversation. FLOW reported on kidney endpoints in people with type 2 diabetes and chronic kidney disease, which is a narrower population than the discussion here usually assumes.

I would rather post the uncertainty than round it away.

The failure mode on Semaglutide half-life is boring rather than dramatic. It is almost always the step everyone assumes was done correctly because it is too simple to get wrong.

Post #21 and I disagree about the size of the effect, not about the direction.

If you are new and reading this thread for the answer to Semaglutide half-life: the answer is conditional, the conditions are in the third reply, and the rest of the thread is worth skipping.

On the injection-day question: the labelling for licensed semaglutide allows the day to be changed provided at least two days separate the two injections. That interval is not arbitrary — it is what stops two doses stacking inside one absorption window.

Speaking for myself and not for anyone else who has posted here.

Semaglutide's structure is a modified backbone with a C18 diacid attached through a spacer. The acylation is the reason for the long half-life and it is also the reason a plain sequence comparison against native GLP-1 is misleading about how the molecule behaves.

If it helps: the failure mode here is usually boring rather than dramatic.

Coming back to post #56, because the follow-up matters more than the original answer.

Solutions of semaglutide can look faintly opalescent without anything being wrong. Visible particulate, fibres or frank cloudiness are a different observation entirely and are worth raising with the supplier rather than reasoning about.

Post #93 put the caveat in the right place and I want to underline it.

Checked the Semaglutide half-life claim against the primary source this morning. It survives, with a narrower scope than the version quoted here. Posting the narrower scope.

Genuine question rather than a rhetorical one: has anyone here actually observed Semaglutide half-life, as opposed to read about it? The thread is long and I cannot tell.